Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05050617 · ClinicalTrials.gov registry record

Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism

A clinical trial of Pulmonary Embolism, sponsored by WellSpan Health.

Recruiting
Registry status
250
Enrollment target
1
Study location

NCT05050617: Recruiting study of Pulmonary Embolism, sponsored by WellSpan Health.

NCT05050617 is a study of Pulmonary Embolism that is actively recruiting participants, run by WellSpan Health. The registered enrollment target is 250 participants, below the 3,053-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05050617, a study of Pulmonary Embolism, is actively recruiting participants, sponsored by WellSpan Health.

RECRUITING
Registry status
250 participants
Enrollment target
1
Study location

Study Summary

This study is an observational, prospective study examining the role point-of-care echocardiography of predicting short term adverse outcomes in emergency department patients with acute pulmonary embolism. The primary objective is to assess the diagnostic performance of ultrasound-guided measures of right ventricular dilation (RVD) and strain in predicting clinical outcomes in acute PE. The secondary objective is to investigate the utility of combining ultrasound-guided measures of RVD and the pulmonary embolism severity index (PESI) score in predicting adverse outcomes in acute PE.

Primary Outcome

Composite of recurrent/worsening VTE (including PE or DVT), new cardiac dysrhythmia, major bleeding, return to the ED, death or need for critical interventions (including advanced cardiac life support, advanced respiratory support, vasopressor support, thrombolysis or new oxygen requirement occurring after initial presentation) occurring within 5 days of acute PE diagnosis

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Point-of-care echocardiography

Study Locations (1)

Pennsylvania

  • Wellspan York Hospital - York

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2021-09-09
Est. Completion 2025-10
WellSpan Health

21 total trials

What NCT05050617 shows while recruiting

NCT05050617 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 3,053-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 1 intervention - of which Point-of-care echocardiography is the first listed.

NCT05050617 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05050617 about?

NCT05050617 is a clinical study titled "Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism". This study is an observational, prospective study examining the role point-of-care echocardiography of predicting short term adverse outcomes in emergency department patients with acute pulmonary embolism. The primary objective is to assess the diagnostic performance of ultrasound-guided measures o...

What is the current status of trial NCT05050617?

This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2021-09-09. Estimated completion is 2025-10.

What conditions does trial NCT05050617 study?

This clinical trial studies the following conditions: Pulmonary Embolism.

What interventions are being tested in trial NCT05050617?

The interventions under investigation include: Point-of-care echocardiography (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05050617?

This trial is sponsored by WellSpan Health, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05050617 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Embolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05050617's enrollment target sits among peer trials

250 22nd of 48 higher than 27 of 48 other Pulmonary Embolism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05050617, the US trial registry maintained by the National Library of Medicine. NCT05050617 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.